Last reviewed · How we verify

12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients

NCT02269176 Phase 3 COMPLETED

Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in China

Details

Lead sponsorBoehringer Ingelheim
PhasePhase 3
StatusCOMPLETED
Enrolment330
Start date2000-07

Conditions

Interventions

Primary outcomes